Prudential Financial Inc. Lowers Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Prudential Financial Inc. cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 3.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 223,288 shares of the biopharmaceutical company’s stock after selling 7,275 shares during the period. Prudential Financial Inc. owned approximately 0.18% of Halozyme Therapeutics worth $10,675,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Heck Capital Advisors LLC purchased a new position in Halozyme Therapeutics during the fourth quarter worth approximately $29,000. CBIZ Investment Advisory Services LLC purchased a new position in shares of Halozyme Therapeutics during the 4th quarter valued at approximately $29,000. Smartleaf Asset Management LLC grew its stake in Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 197 shares during the period. Venturi Wealth Management LLC purchased a new stake in Halozyme Therapeutics in the 4th quarter worth $69,000. Finally, Parkside Financial Bank & Trust raised its position in Halozyme Therapeutics by 21.8% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 322 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at $10,126,499.68. This trade represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the sale, the director now directly owns 38,611 shares in the company, valued at $2,173,799.30. This trade represents a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 31,697 shares of company stock worth $1,754,451 in the last 90 days. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $63.84 on Friday. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.73 and a fifty-two week high of $66.00. The firm has a market capitalization of $7.89 billion, a P/E ratio of 18.61, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The stock’s fifty day moving average is $59.16 and its two-hundred day moving average is $54.88. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. On average, research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on HALO. Wells Fargo & Company cut their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Benchmark reiterated a “buy” rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Finally, Piper Sandler lifted their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $62.78.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.